Whitepaper & Case Study: Why CAPA Still Matters, and How a Major Medical Device Company Implemented a Successful System
THANK YOU. Your request will be processed promptly.
Once again, the FDA's most common 483 observation cited for medical device manufacturers is the failure to maintain a proper Corrective and Preventive Action System (CAPA). In this updated white paper, you'll learn from former FDAers on how to properly implement an effective CAPA system and prepare for an FDA inspection. In addition, you will also read about how Bausch & Lomb successfully installed a worldwide CAPA system.
To request your paper, or any additional information, please fill out the form below.
* Denotes a required field
People Are Talking
Chief Information Officer
See the Customer Video:Alcon Labs discusses their centralized FDA compliant CAPA system used across multiple facilities > Explore Webcasts
Easy In, Easy Up & Running
AssurX is quick and simple to configure and deploy. And, its open interface integrates with any existing information systems and databases.> Learn More